Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy

Pfizer

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Other: SC anti-TNF

Study type: Observational

Funder types: Industry

Identifiers

NCT01521884

B1801046 (Other Identifier)

0881A1-4748

Details and patient eligibility

About

People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.

Full description

Observational prospective study Purely descriptive

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients who:

• Are active RA patients (as judged by treating MD)
• Are 18 years of age or older at time of consent
• Are scheduled by their rheumatologist to initiate SC anti-TNF-α therapy + MTX

Exclusion criteria

Use of biologics (or any experimental drug) in the last 3 months before initiation of SC anti-TNF-α therapy.

Participation in other clinical or observational trials

Trial design

62 participants in 1 patient group

RA Patients treated with SC anti-TNF

Treatment:

Other: SC anti-TNF